Can biology trump anatomy? Do all node-positive patients with breast cancer need chemotherapy?

Journal of Clinical Oncology

Volumn 25, Issue 18, 2007, Pages 2501-2503

  Henry, N Lynn ^a   Hayes, Daniel F ^a  

^a UNIVERSITY OF MICHIGAN COMPREHENSIVE CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; DOXORUBICIN; ESTROGEN RECEPTOR; FLUOROURACIL; GONADORELIN AGONIST; GOSERELIN; METHOTREXATE; TAMOXIFEN;

ADJUVANT CHEMOTHERAPY; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; EDITORIAL; HUMAN; OVARY INSUFFICIENCY; PRIORITY JOURNAL; TREATMENT OUTCOME; TREATMENT RESPONSE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CYCLOPHOSPHAMIDE; FLUOROURACIL; HUMANS; LEUPROLIDE; LYMPHATIC METASTASIS; METHOTREXATE; PATIENT SELECTION; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TAMOXIFEN;

EID: 34447251650     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2007.11.3290     Document Type: Editorial

References (27)

1. American Cancer Society: Cancer Facts and Figures, 2007. http://www .cancer.org/downloads/STT/CAFF2007PWSecured.pdf
2. Berry DA, Cronin KA, Plevritis SK, et al: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med 353:1784-1792, 2005
3. Carlson RW, Anderson BO, Burstein HJ, et al: Breast cancer. J Natl Compr Canc Netw 3:238-289, 2005
4. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: An overview of the randomised trials. Lancet 365:1687-1717, 2005
5. Lippman ME, Allegra JC, Thompson EB, et al: The relation between estrogen receptors and response rate to cytotoxic chemotherapy in metastatic breast cancer. N Engl J Med 298:1223-1228, 1978
6. Berry DA, Cirrincione C, Henderson IC, et al: Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer. JAMA 295:1658-1667, 2006
7. Polychemotherapy for early breast cancer: An overview of the randomised trials: Early Breast Cancer Trialists' Collaborative Group. Lancet 352:930-942, 1998
8. Gelber RD, Bonetti M, Castiglione-Gertsch M, et al: Tailoring adjuvant treatments for the individual breast cancer patient. Breast 12:558-568, 2003
9. Anderson WF, Chatterjee N, Ershler WB, et al: Estrogen receptor breast cancer phenotypes in the Surveillance, Epidemiology, and End Results database. Breast Cancer Res Treat 76:27-36, 2002
10. Castiglione-Gertsch M, O'Neill A, Price KN, et al: Adjuvant chemotherapy followed by goserelin versus either modality alone for premenopausal lymph node-negative breast cancer: A randomized trial. J Natl Cancer Inst 95:1833-1846, 2003
11. Kaufmann M, Jonat W, Blamey R, et al: Survival analyses from the ZEBRA study: Goserelin (Zoladex) versus CMF in premenopausal women with node-positive breast cancer. Eur J Cancer 39:1711-1717, 2003
12. Thomson CS, Twelves CJ, Mallon EA, et al: Adjuvant ovarian ablation vs CMF chemotherapy in premenopausal breast cancer patients: Trial update and impact of immunohistochemical assessment of ER status. Breast 11:419-429, 2002
13. Ejlertsen B, Mouridsen HT, Jensen MB, et al: Similar efficacy for ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: From a randomized comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J Clin Oncol 24:4956-4962, 2006
14. Wolff AC, Davidson NE: Still waiting after 110 years: The optimal use of ovarian ablation as adjuvant therapy for breast cancer. J Clin Oncol 24:4949-4951, 2006
15. Schmid P, Untch M, Kossé V, et al: Leuprorelin acetate every-3-months depot versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant treatment in premenopausal patients with node-positive breast cancer: The TABLE study. J Clin Oncol 25:2509-2515, 2007
16. Engelsman E, Klijn JCM, Rubens RD, et al: "Classical" CMF versus a 3-weekly intravenous CMF schedule in postmenopausal patients with advanced breast cancer: An EORTC breast cancer co-operative group phase III trial (10808). Eur J Cancer 27:966-970, 1991
17. Goldhirsch A, Coates AS, Colleoni M, et al: Adjuvant chemoendocrine therapy in postmenopausal breast cancer: Cyclophosphamide, methotrexate, and fluorouracil dose and schedule may make a difference: International Breast Cancer Study Group. J Clin Oncol 16:1358-1362, 1998
18. Pritchard KI, Shepherd LE, O'Malley FP, et al: HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 354:2103-2111, 2006
19. Yamauchi H, Stearns V, Hayes DF: The role of c-erbB-2 as a predictive factor in breast cancer. Breast Cancer 8:171-183, 2001
20. Hayes DF, Thor A, Dressier L, et al: HER2 predicts benefit from adjuvant paclitaxel after AC in node-positive breast cancer: CALGB 9344. J Clin Oncol 24:18S, 2006 (suppl; abstr 510)
21. Henderson IC, Berry DA, Demetri GD, et al: Improved outcomes from adding sequential paclitaxel but not from escalating doxorubicin dose in an adjuvant chemotherapy regimen for patients with node-positive primary breast cancer. J Clin Oncol 21:976-983, 2003
22. Albain K, Barlow W, O'Malley F, et al: Concurrent (CAFT) versus sequential (CAF-T) chemohormonal therapy (cyclophosphamide, doxorubicin, 5-fluorouracil, tamoxifen) versus T alone for postmenopausal, node-positive, estrogen (ER) and/or progesterone (PgR) receptor-positive breast cancer: Mature outcomes and new biologic correlates on phase III intergroup trial 0100 (SWOG-8814). Breast Cancer Res Treat 88, 2004 (abstr 37)
23. Fisher B, Dignam J, Wolmark N, et al: Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer. J Natl Cancer Inst 89:1673-1682, 1997
24. International Breast Cancer Study Group: Randomized controlled trial of ovarian function suppression plus tamoxifen versus the same endocrine therapy plus chemotherapy: Is chemotherapy necessary for premenopausal women with node-positive, endocrine responsive breast cancer? First results of International Breast Cancer Study Group Trial 11-93. Breast 10:130-138, 2001 (suppl 3)
25. van't Veer LJ, Paik S, Hayes DF: Gene expression profiling of breast cancer: A new tumor marker. J Clin Oncol 23:1631-1635, 2005
26. Paik S, Shak S, Tang G, et al: A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351:2817-2826, 2004
27. Paik S, Tang G, Shak S, et al: Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer. J Clin Oncol 24:3726-3734, 2006